Medoclazide

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Medoclazide

Quick Facts

Property Description
Active ingredient Gliclazide
Form Tablets (Oral)
Pharmacological class Sulfonylurea, Antidiabetic Agent
General purpose Blood Glucose Control
Origin Synthetic, Sulfonamide group

Medoclazide is a synthetic, single-ingredient, prescription-only medication whose active component is Gliclazide, chemically belonging to the sulfonamide group. It is classified as an oral hypoglycemic agent used to help manage elevated blood sugar levels. Medoclazide and its generic forms are widely recognized for their role in the long-term metabolic support of patients.


What Type of Medicine is Medoclazide?

Medoclazide is a member of the second-generation sulfonylurea class of medicines. The active substance, Gliclazide, functions as an insulin secretagogue, meaning it prompts the pancreatic beta-cells to secrete more of the body's own insulin. This mechanism supports the management of high blood sugar, as this class of agents is designed to improve insulin secretion to address elevated blood glucose levels. The essential conclusion for the patient is that this medicine actively supports the body's ability to release the necessary hormone to process sugar.


How Does Medoclazide Come: Form and Presentation

Medoclazide is administered via the oral route and is supplied in the standard dosage form of tablets. The medication is available in distinct physical types, commonly including both standard-release and modified-release (MR) tablets. The modified-release formulation, a key differentiating feature, provides a sustained release of Gliclazide over time. This means the pharmaceutical design of the MR tablet helps deliver the active ingredient smoothly and consistently across the day, making it a suitable choice for adults requiring stable blood glucose control.

What side effects are possible with Medoclazide?

Possible Side Effects and Safety Information

The official safety profile for Medoclazide (active ingredient Metoclopramide) is structured around categories of adverse reactions documented in regulatory sources such as the FDA and EMA. This framework includes classifying effects by frequency and the body system affected, ensuring transparent communication of risk.

Regulatory Classification of Adverse Reactions

Adverse effects are grouped according to the specific body system or organ class affected. These include Nervous System Disorders, Psychiatric Disorders, Gastrointestinal Disorders, and Endocrine Disorders.

Reactions are classified by how often they occur:

  • Very Common (ge 1/10): Drowsiness, fatigue, lassitude, and restlessness.
  • Common (ge 1/100 to <1/10): Headache, diarrhea, and depression.

Serious Adverse Reactions and Duration-Related Safety

Regulatory labeling highlights specific Serious Adverse Reactions (SAR). The most prominent SAR is Tardive Dyskinesia (TD), a movement disorder often subject to a Boxed Warning by the FDA. The risk of developing TD is documented to increase with the duration of treatment and the total cumulative dose. Therefore, official safety statements advise against continuous treatment exceeding 12 weeks (three months) in most cases.

Other SARs include Neuroleptic Malignant Syndrome (NMS), a rare but severe condition, and acute involuntary movements known as Extrapyramidal Symptoms (EPS), which can occur early in treatment or even after a single dose. Rare reports of severe cardiovascular effects, such as cardiac arrest and circulatory collapse, are also documented.

Population-Specific Safety Constraints

The official safety profile outlines constraints for specific populations. For instance, dose reduction is recommended for individuals with moderate to severe renal impairment or severe hepatic impairment due to reduced clearance of the medicine. The risk of Extrapyramidal Disorders is noted as increased in the pediatric population, and older adults may also be more susceptible to serious movement disorders.

Overdose and Emergency Response

Overdose and when to seek help

Medoclazide overdose is characterized by documented effects primarily related to the central nervous system and motor function. Common manifestations described in regulatory information include drowsiness, disorientation, and confusion. A significant clinical presentation of overdose is the occurrence of Extrapyramidal reactions (EPS), which are severe movement disorders.


The official regulatory profile associates overdose with life-threatening outcomes, specifically reporting associations with Neuroleptic Malignant Syndrome (NMS) and the serious risk of methemoglobinemia. Due to the potential for these severe complications, immediate medical attention is required upon any suspected overdose, regardless of the severity of initial symptoms. Health authorities state that contact should be made with a health care practitioner or regional poison control centre.


The management described in official documents is largely symptomatic and supportive. For severe effects like EPS, specific treatments (e.g., anticholinergic agents) are utilized. For methemoglobinemia, the specific antidote methylene blue is administered. Specific overdose risks are noted for neonates, who are particularly vulnerable to methemoglobinemia, and infants and children, where misadministration has led to events like seizures. Regulatory data notes that drug removal procedures such as dialysis are not likely to be effective.

Therapeutic Uses of Medoclazide

What Medoclazide Treats: Main Uses and Benefits

The primary therapeutic domain of Medoclazide (active ingredient metoclopramide) is used for managing symptoms related to physical discomfort in the gastrointestinal tract and helps address symptoms related to heightened physiological activity, such as nausea and vomiting. It is applied across domains where additional symptomatic support is needed.

Medoclazide is commonly used across conditions presenting with acute episodes, including managing symptoms associated with gastroesophageal reflux (GER) and supporting symptomatic management for diabetic gastroparesis. These are conditions where symptoms may intensify temporarily or involve episodic manifestations.

In clinical scenarios, Medoclazide is often used when symptoms intensify and supportive relief is needed, such as that associated with chemotherapy or post-surgical states. Its use may help patients cope more steadily with symptom fluctuations and helps improve day-to-day comfort during symptomatic periods.


Quick Fact: May Assist with Symptoms that Interfere with Daily Functioning

This supportive care may assist with maintaining functional stability and contributes to easing the overall symptom load.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Medoclazide has strictly defined eligibility criteria based on official regulatory documents. The medicine is contraindicated and must not be used by individuals with a number of serious conditions, including gastrointestinal hemorrhage, mechanical obstruction, or perforation. Absolute non-eligibility also applies to patients with pheochromocytoma, epilepsy or seizures, or a history of tardive dyskinesia.

Population Restrictions

  • Age: The medicine is contraindicated in children aged less than 1 year. For older pediatric patients, the FDA generally does not recommend use, while EU guidelines restrict use to a second-line option for specific indications. Older adults require consideration for a lower starting dosage.
  • Organ Function: Patients with renal impairment or severe hepatic impairment require a reduction in the initial dosage as mandated by the prescribing label.
  • Pregnancy/Lactation: Use is not recommended during breastfeeding and must be avoided at the end of pregnancy due to the risk of extrapyramidal syndrome in the newborn.

What should I know about interactions with other medicines?

Medoclazide (metoclopramide) interacts with several medicinal products and substances through documented pharmacokinetic and pharmacodynamic mechanisms. Co-administration with Levodopa or other Dopaminergic Agonists is formally contraindicated due to mutual antagonism that reduces the therapeutic efficacy of both agents. The drug's metabolism via the CYP2D6 enzyme pathway is a key area of interaction. Co-administration with strong CYP2D6 Inhibitors (such as fluoxetine or paroxetine) results in increased systemic concentrations of Medoclazide, which necessitates a mandatory dosage reduction. Similar dose adjustments are required for patients who are CYP2D6 Poor Metabolizers.

A major category of pharmacodynamic interactions involves Central Nervous System (CNS) Depressants, including alcohol. Concomitant use with these agents creates an additive effect that increases the risk of CNS depression. Use with Neuroleptics or Antipsychotic Agents carries an increased risk of severe motor disorders, including Extrapyramidal Symptoms (EPS). Furthermore, Medoclazide's effect on accelerating gastric emptying is documented to alter the absorption of other oral medications, potentially decreasing the exposure of drugs like Digoxin and increasing the absorption of others like Paracetamol. For paediatric patients (1–18 years), a strict minimal interval of 6 hours between administrations must be respected. Dosage must also be reduced in cases of documented renal or severe hepatic impairment.

Mechanism of Action

How Medoclazide Works

Medoclazide (Gliclazide) acts as an insulin secretagogue, meaning it prompts the body to release its own stored insulin via a specific, targeted molecular cascade. Its mechanism is confined to the cellular and systemic processes of glucose regulation, and results in a systemic alteration of glucose homeostasis.


Targeting the K ATP Channel in the Pancreas

The core mechanism involves the active ingredient binding to the Sulfonylurea Receptor 1 ( SUR1), a specific component of the ATP-sensitive potassium channel ( K ATP channel) on pancreatic beta-cells. This binding event causes the channel to close, stopping the outflow of potassium ions ( K^+) and initiating a chain of electrical signals within the cell. This channel blockade is a peripheral action that sets the stage for hormone release.


Causal Cascade: From Ion Flow to Insulin Release

The closure of the potassium channel leads to membrane depolarization of the beta-cell. This change in electrical charge triggers the opening of voltage-dependent calcium channels, resulting in a rapid influx of calcium ions ( Ca^2+). The increased intracellular calcium concentration serves as the essential messenger, commanding the exocytosis of stored insulin granules. The physiological consequence of this targeted action is an augmentation of systemic insulin release.


Physiological Consequence and Mechanistic Limitations

The higher circulating levels of insulin facilitate the transport of glucose out of the bloodstream and simultaneously suppress glucose output from the liver. These actions define the physiological changes resulting from the mechanism on glucose levels. Critically, the drug's mechanism is only effective if the patient has residual functional beta-cells capable of synthesizing and storing insulin, as the drug only releases the hormone, it does not create it.

Dosage and Administration Information

Medoclazide (metoclopramide) is used following specific administration protocols. The approved routes include Oral administration (tablets or solution) and Parenteral Injection (intravenous or intramuscular) typically in a supervised setting.

Administration and Dosing Regimens

The standard pattern for continuous oral use is four times daily (QID). Oral doses are specifically timed to be taken on an empty stomach: 30 minutes before each meal and once again at bedtime.

Indication Standard Oral Dose Max Duration Constraint
Symptomatic GER 10 mg to 15 mg QID Do not exceed 12 weeks
Diabetic Gastroparesis 10 mg QID Do not exceed 12 weeks

A minimum interval of 6 hours is observed between any two doses. This time constraint applies regardless of the indication.

Procedural and Population Constraints

The procedural administration of the intravenous form requires the dose to be injected slowly over a period of at least 1 to 3 minutes. For specific populations, including older adults and patients with renal or hepatic impairment, dose reduction is indicated or a lower starting dosage is considered (e.g., 5 mg QID). The continuous use of oral tablets is primarily indicated for adults.

Recent Clinical Evidence

Medoclazide: Recent Clinical Evidence

Evidence for Use in Diabetic Gastroparesis

Medoclazide (active ingredient metoclopramide) was studied for outcomes related to physical discomfort in adults with diabetic gastroparesis. This research examined this use primarily through short-term, randomized, controlled clinical trials (RCTs) and systematic reviews. These studies focused on patient-reported outcomes describing perceived discomfort, specifically by monitoring symptoms such as nausea, vomiting, and abdominal fullness. Trials also monitored changes in objective gastric emptying rates. Follow-up durations were limited in the key research, as regulatory guidance restricts continuous treatment to a maximum of 12 weeks. Therefore, the long-term effects are not fully established regarding outcomes related to long-term symptom management.


Evidence for Use in Acute Nausea and Vomiting

Medoclazide was evaluated in research exploring short-term symptom changes related to acute nausea and vomiting linked to chemotherapy or surgical procedures. The evidence base was observed in randomized controlled trials (RCTs) and subsequent meta-analyses, which included groups receiving placebo and other active agents. The studies monitored outcomes describing episodic or acute changes, such as the frequency of vomiting and the need for rescue medications. Evidence is limited to the immediate, very short-term management of symptoms. Regulatory restrictions outside the United States limit the use of Medoclazide for these acute indications to a maximum of five days.


Evidence Gaps and Areas of Uncertainty

Research exploring the short-term use of Medoclazide for gastroesophageal reflux (GER) is based on older trial data, and some international regulators concluded that the evidence for consistent symptomatic findings in GER remains low. Across all uses, follow-up durations were limited; thus, the data's contribution to understanding long-term symptom patterns is not fully established. Research involving pediatric populations is restricted, and comparative evidence is lacking for many patient subgroups.

Key Studies & References MedlinePlus Drug Information on Sulfonylurea Agents

Frequently Asked Questions (FAQ)

Common questions about Medoclazide (FAQ)

Q: Is Medoclazide a type of antibiotic or something else?

A: Medoclazide (active ingredient metoclopramide) is not an antibiotic. According to official product information, it is classified as a dopamine receptor antagonist, as well as an antiemetic and prokinetic agent. This means it is used to help control nausea, vomiting, and to aid in moving food through the digestive tract.


Q: How quickly should I expect Medoclazide to start working?

A: Studies and official information indicate that the pharmacological effects typically begin within 30 to 60 minutes after taking an oral dose. The effects generally persist for about one to two hours. This timeframe can vary depending on individual factors and the specific formulation used.


Q: What happens if you miss a dose of Medoclazide?

A: Official patient information often suggests that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped entirely. It is important that a double dose is not taken to make up for a missed one.


Q: Is Medoclazide available as a generic version?

A: Yes, the active ingredient in Medoclazide, metoclopramide hydrochloride, is widely available in generic form. It can be found under its generic name in addition to various brand names.


Q: Can Medoclazide be crushed or split if a person has trouble swallowing?

A: Official prescribing information does not generally recommend crushing or splitting standard tablets. If difficulty swallowing is a concern, specialized orally disintegrating tablets (ODTs) are available. ODTs are designed to dissolve on the tongue and should not be crushed or split either.


Q: What foods should be avoided when taking Medoclazide?

A: The official instructions emphasize that Medoclazide should be taken on an empty stomach, typically 30 minutes before each meal and once more at bedtime. Patients are generally advised to continue their regular diet, as specific food avoidance is not mandated by the regulatory label for this drug.


Q: What happens if you take Medoclazide for longer than planned?

A: Continuous use of Medoclazide for longer than 12 weeks is generally not recommended by regulatory bodies. This is because the risk of developing a serious, long-term movement disorder called Tardive Dyskinesia increases with the duration of treatment and the total cumulative dose over time.


Q: What are the signs that Medoclazide is actually working?

A: Medoclazide is approved to help manage symptoms linked to certain digestive conditions. Signs that the medication is working may include the relief of uncomfortable symptoms like persistent nausea, vomiting, and feelings of fullness after meals.


Q: Why do doctors prescribe Medoclazide instead of an alternative treatment?

A: Medoclazide is approved for specific medical conditions, such as managing diabetic gastroparesis and providing short-term treatment for symptomatic gastroesophageal reflux (GERD) when other conventional therapies have not been successful. The decision to prescribe it over an alternative is a clinical choice made by a healthcare provider.


Q: Does Medoclazide interact with any common herbal remedies?

A: There is limited information in regulatory sources to confirm the safety of complementary, herbal, or natural remedies when taken with Medoclazide. These products are generally not tested against prescription medications in the same way, and caution is therefore noted.


Q: Is Medoclazide safe during pregnancy or breastfeeding?

A: Regarding pregnancy, official information states that use must be avoided near the end of pregnancy due to the potential risk of extrapyramidal symptoms in the newborn. Medoclazide passes into breast milk, and its use is therefore not generally recommended during breastfeeding.


Q: Is there a maximum time someone can safely use Medoclazide?

A: Yes, official safety statements advise that continuous treatment should generally not exceed 12 weeks (three months). This restriction is put in place because a longer duration of use is associated with an increased risk of developing Tardive Dyskinesia.


Q: Are headaches a common side effect when starting Medoclazide?

A: Headache is listed in official documents as a common adverse reaction, meaning it occurs in more than 1 out of 100 people. While it is a common side effect, regulatory data does not specifically state that the frequency is higher when a person is first starting the medication.


Q: Does taking Medoclazide affect your sleep?

A: Yes, taking Medoclazide can affect sleep. Official adverse reaction data lists drowsiness as a very common side effect. Less frequently, side effects such as insomnia (trouble sleeping) and restlessness (known as akathisia) have also been reported, which may interfere with normal sleep patterns.


Q: Is it necessary to avoid alcohol completely while on Medoclazide?

A: Using Medoclazide alongside alcohol is discouraged because it increases Central Nervous System (CNS) depressant effects, such as drowsiness. Official product information suggests avoiding or significantly limiting alcohol consumption while taking this medication.


Q: What should I do if I experience a very rare side effect from Medoclazide?

A: Regulatory documents state that any signs of a serious side effect, such as uncontrolled body movements (Extrapyramidal Symptoms or Tardive Dyskinesia), warrant immediate medical consultation. It is recommended to contact a healthcare professional right away.


Q: Has Medoclazide been studied in combination with other major treatments?

A: Yes, the regulatory label details known interactions with several major drug classes, including CNS depressants, dopamine agonists, and certain liver enzyme inhibitors. These interaction warnings are necessary because the drug is often co-administered with other medications as part of a patient's regimen.


Q: Can Medoclazide cause weight changes?

A: Official information indicates that Medoclazide can sometimes cause fluid retention, which is linked to a temporary increase in aldosterone hormone levels. This may be associated with sudden or unexpected weight gain in some people.


Q: Is it normal to have mild stomach upset when starting Medoclazide?

A: Yes, certain gastrointestinal issues are noted as common side effects of this medication. Official reports list diarrhea and nausea as possible adverse reactions, which may be experienced by some people as a general feeling of stomach upset, particularly when first starting treatment.


Q: Are there any known interactions between Medoclazide and supplements like Vitamin D or magnesium?

A: Regulatory sources focus on interactions between prescribed medications and do not contain sufficient information to confirm the safety of taking specific vitamins or supplements, like Vitamin D or magnesium, alongside Medoclazide. It is best to discuss all supplements with a healthcare provider.


Q: What is the main benefit people seek from taking Medoclazide?

A: The main therapeutic goal for patients taking Medoclazide is relief from severe and debilitating digestive symptoms. This includes managing chronic nausea, preventing vomiting, and reducing abdominal discomfort related to conditions like diabetic gastroparesis.

How should Medoclazide be stored and disposed of?

Medoclazide (Gliclazide) storage and disposal instructions are defined by regulatory documents to ensure product stability and safety.

Storage Requirements

Official labeling mandates that the tablets must be stored below 25 C (77 F) and protected from moisture. The medicine must not be refrigerated or frozen, as these environments can compromise the stability of the drug. Tablets should be kept in the original blister packaging to maintain protection.

Handling and Child Safety

Medoclazide must be kept out of the sight and reach of children to prevent accidental ingestion. The stated shelf-life is valid only when the product is stored under the specified temperature and environmental conditions.

Disposal Instructions

Unused or expired Medoclazide must be disposed of in accordance with local regulatory requirements, such as approved drug take-back programs. The product must not be discarded via wastewater or thrown directly into household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Medoclazide found in:

A-Z Index: